Improving quality of care in inflammatory bowel disease: what changes can be made today?

[1]  G. Rogler,et al.  Diagnostic Delay in Crohn's Disease Is Associated With a Complicated Disease Course and Increased Operation Rate , 2013, The American Journal of Gastroenterology.

[2]  L. Peyrin-Biroulet,et al.  Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases: A Systematic Review , 2013, Inflammatory bowel diseases.

[3]  G. Tober.  Motivational Interviewing: Helping People Change , 2013 .

[4]  D. Hommes,et al.  Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. , 2013, Journal of Crohn's & colitis.

[5]  B. Sands,et al.  A Survey of Current Practice of Venous Thromboembolism Prophylaxis in Hospitalized Inflammatory Bowel Disease Patients in the United States , 2013, Journal of clinical gastroenterology.

[6]  M. Cvancarova,et al.  Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study , 2012, Gut.

[7]  P. Irving.  The future developments in inflammatory bowel disease care , 2012, Frontline Gastroenterology.

[8]  Edward T. Cokely,et al.  Using Visual Aids to Improve Communication of Risks about Health: A Review , 2012, TheScientificWorldJournal.

[9]  S. Vermeire,et al.  P406 A European Crohn's and ulcerative colitis patient life IMPACT survey , 2012 .

[10]  S. Danese.  New therapies for inflammatory bowel disease: from the bench to the bedside , 2011, Gut.

[11]  C. McHorney,et al.  Frequency of and reasons for medication non‐fulfillment and non‐persistence among American adults with chronic disease in 2008 , 2011, Health expectations : an international journal of public participation in health care and health policy.

[12]  F. Carrat,et al.  Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort , 2011, Alimentary pharmacology & therapeutics.

[13]  L. Peyrin-Biroulet,et al.  Surgery for adult Crohn's disease: what is the actual risk? , 2011, Gut.

[14]  K. Van Steen,et al.  Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  Marian O’Connor,et al.  Criteria for success using an inflammatory bowel disease nurse telephone service , 2011 .

[16]  N. LeLeiko,et al.  Real‐time tool to display the predicted disease course and treatment response for children with Crohn's disease , 2011, Inflammatory bowel diseases.

[17]  H. Tilg,et al.  Development of the Crohn's disease digestive damage score, the Lémann score , 2010, Inflammatory bowel diseases.

[18]  Johan Burisch,et al.  E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided ‘Constant-care’ approach , 2010, Gut.

[19]  J. Duncan,et al.  Inflammatory Bowel Disease Nursing , 2010 .

[20]  U. Kopylov,et al.  The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful , 2010, Gut.

[21]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[22]  E. Kuipers,et al.  Patients’ Preferences regarding Shared Decision-Making in the Treatment of Inflammatory Bowel Disease: Results from a Patient-Empowerment Study , 2010, Digestion.

[23]  P. Rutgeerts,et al.  Predicting the response to infliximab from trough serum levels , 2009, Gut.

[24]  M. Dimatteo,et al.  Physician Communication and Patient Adherence to Treatment : A Meta-analysis , 2018 .

[25]  R. Horne,et al.  Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease , 2009, Inflammatory bowel diseases.

[26]  G. Gigerenzer,et al.  Using icon arrays to communicate medical risks: overcoming low numeracy. , 2009, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[27]  K. Bendtzen,et al.  Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies , 2009, Scandinavian journal of gastroenterology.

[28]  C. Ricci,et al.  The multidisciplinary team for management of inflammatory bowel diseases. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[29]  G. Kaplan,et al.  Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. , 2008, Gastroenterology.

[30]  F Reed Johnson,et al.  Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. , 2007, Gastroenterology.

[31]  M. Schwab,et al.  Adherence to thiopurine treatment in out‐patients with Crohn’s disease , 2007, Alimentary pharmacology & therapeutics.

[32]  V. Cooper,et al.  Patients' Perceptions of Highly Active Antiretroviral Therapy in Relation to Treatment Uptake and Adherence: The Utility of the Necessity-Concerns Framework , 2007, Journal of acquired immune deficiency syndromes.

[33]  G. Mantzaris,et al.  How Adherent to Treatment With Azathioprine Are Patients With Crohn's Disease in Long‐term Remission? , 2007, Inflammatory bowel diseases.

[34]  D. Rampton,et al.  Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics , 2006, European journal of gastroenterology & hepatology.

[35]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[36]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[37]  John A. Baron,et al.  The framing effect of relative and absolute risk , 1993, Journal of General Internal Medicine.

[38]  M. Frisch,et al.  Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[40]  H. Tilg,et al.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[41]  Mahendra Patel,et al.  Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence , 2009 .